AAD Logo
By Allison Evans, Assistant Managing Editor, April 1, 2024 Over the last decade, research and development of Janus kinase (JAK) inhibitors have exploded. Three years ago, JAK inhibitors were on the cusp of being available for dermatologic indications. In this short window, six JAK inhibitors have entered the dermatology space, offering options where none had previously existed — vitiligo and alopecia areata — while expanding treatment options for other conditions, including atopic dermatitis and psoriasis.